BridgeBio

BridgeBio Pharma, Inc. (BridgeBio) is a biopharmaceutical company established to discover, create, test, and deliver transformative medicines for patients with genetic diseases and cancers driven by well-defined genetic factors. BridgeBio has over 30 development programs ranging from early scientific research to advanced clinical trials, and its commercial organization focuses on delivering the company’s two approved therapies. Founded in 2015, BridgeBio’s team consists of experienced drug discoverers, developers, and innovators dedicated to applying cutting-edge advancements in genetic medicine to help patients as quickly as possible.